Innovations, Opportunities, and Challenges for Predicting Alteration in Drug-Metabolizing Enzyme and Transporter Activity in Specific Populations.
Saved in:
| Title: | Innovations, Opportunities, and Challenges for Predicting Alteration in Drug-Metabolizing Enzyme and Transporter Activity in Specific Populations. |
|---|---|
| Authors: | Chothe PP; Drug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Waltham, Massachusetts (P.P.C., D.R.); Division of Infectious Disease Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland (V.A.); Department of Pharmaceutical Sciences, Washington State University, Spokane, Washington (B.P.); and Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, R&D, Stevenage, United Kingdom (K.T.) paresh.chothe@astrazeneca.com., Arya V; Drug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Waltham, Massachusetts (P.P.C., D.R.); Division of Infectious Disease Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland (V.A.); Department of Pharmaceutical Sciences, Washington State University, Spokane, Washington (B.P.); and Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, R&D, Stevenage, United Kingdom (K.T.)., Prasad B; Drug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Waltham, Massachusetts (P.P.C., D.R.); Division of Infectious Disease Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland (V.A.); Department of Pharmaceutical Sciences, Washington State University, Spokane, Washington (B.P.); and Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, R&D, Stevenage, United Kingdom (K.T.)., Ramsden D; Drug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Waltham, Massachusetts (P.P.C., D.R.); Division of Infectious Disease Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland (V.A.); Department of Pharmaceutical Sciences, Washington State University, Spokane, Washington (B.P.); and Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, R&D, Stevenage, United Kingdom (K.T.)., Taskar K; Drug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Waltham, Massachusetts (P.P.C., D.R.); Division of Infectious Disease Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland (V.A.); Department of Pharmaceutical Sciences, Washington State University, Spokane, Washington (B.P.); and Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, R&D, Stevenage, United Kingdom (K.T.). |
| Source: | Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2023 Dec; Vol. 51 (12), pp. 1547-1550. Date of Electronic Publication: 2023 Sep 29. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Country of Publication: Netherlands NLM ID: 9421550 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-009X (Electronic) Linking ISSN: 00909556 NLM ISO Abbreviation: Drug Metab Dispos Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
